SPI1 and cancer: We found that SPIB expression was significantly associated with six immune infiltrating cells in most cancers, except UCS, UVM, and DLBC, consistent with previous studies that reported that therapeutic targeting of SPIB/SPI1 promotes the interaction of cancer cells and neutrophils to inhibit aerobic glycolysis and cancer progression [25].